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In March of 1993, I learned from Marcy McDonald that the
gene for Huntington disease (HD) had been identified by an
international collaboration of researchers. The excitement sur-
rounding this finding was considerable, as one might expect;
however, the stunning aspect of the discovery was the detection
of an expanded run of the amino acid glutamine in patients
affected with HD. This meant that there was a second neu-
rodegenerative disorder caused by an expanded glutamine re-
peat (the first being Kennedy disease, a.k.a. spinal and bulbar
muscular atrophy), and the fact that it was HD made the
discovery all the more spectacular. Over the past 10 years,
CAG trinucleotide-repeat expansions encoding hyperextended
polyglutamine tracts have been identified as the cause of nine
inherited neurodegenerative diseases. These discoveries have
created an entirely new field of research that has attracted the
attention of molecular biologists, model-organism geneticists,
and protein biochemists, in addition to clinical neurologists
and medical geneticists. The polyglutamine-repeat diseases
comprise HD, Kennedy disease, six types of spinocerebellar
ataxia, and an exceedingly rare disorder known as dentato-
rubral-pallidoluysian atrophy or, in North Carolina, as Haw
River syndrome.
One hallmark of the CAG–polyglutamine repeat diseases is
the genetic phenomenon of anticipation, which is defined as
worsening disease severity due to earlier age at onset andmore-
rapid progression of one’s illness in succeeding generations of
an affected pedigree. (Anticipation was originally described at
the turn of the last century but was dismissed in the 1950s by
the well-known geneticist Lionel Penrose as being caused by
ascertainment bias.) Once it became clear that anticipation is
a distinctive feature of the trinucleotide-repeat diseases and
that the molecular explanation for anticipation is the pro-
gressive lengthening of the triplet-repeat tract as it is unstably
transmitted from one generation to the next, gene identification
for inherited neurological diseases greatly accelerated. By
1996, considerable progress had been made in realizing that
one group of the so-called trinucleotide-repeat diseases all in-
volved expansions of a CAG triplet tract in the coding region
of the respective genes responsible for each polyglutamine dis-
order. With strong evidence supporting the notions that poly-
glutamine-expansion tracts are dominant gain-of-functionmu-
tations that cause disease by the adoption of an abnormal
structural conformation and that the disease process could be
modeled in mice, Peter Harper and Max Perutz organized a
Royal Society meeting to address the molecular basis of poly-
glutamine neurodegeneration. In 1998, this meeting brought
together leading researchers from a variety of disciplines, all
interested in glutamine-repeat disease. The outcome of the
1998 Royal Society meeting is a new book, entitledGlutamine
Repeats and Neurodegenerative Diseases: Molecular Aspects.
Peter Harper and Max Perutz, who also serve as the editors
of this scholarly compilation, have attempted to provide a
genetic and molecular overview of the ever-expanding poly-
glutamine disease field. As both Dr. Harper and Dr. Perutz
have played pivotal roles in the development of this field, they
possess a keen appreciation of the significance of the advances
presented in this work. In the glutamine-repeat diseases, an
expansion of a polyglutamine tract is the causal event leading
to disease pathology through a proposed “gain-of-function”
mechanism. The gain-of-function property of the polygluta-
mine-expansion mutation is acquired when a run of glutamine
residues crosses a critical length threshold and adopts a novel
physical conformation. Dr. Max Perutz hypothesized that this
altered structure resulted from the self-association of beta-
pleated sheets of polyglutamine, a prediction that has been
borne out by further investigation. How this altered structure
leads to pathology is the focus of much of the work summa-
rized in Glutamine Repeats and Neurodegenerative Diseases:
Molecular Aspects and remains an area of intense research
activity to this day. Many of the experimental studies that have
led to the dominant paradigms in the polyglutamine disease
field—the necessity of nuclear localization, proteolytic cleavage
of polyglutamine-containing proteins, aberrant protein-protein
interactions, and the phenomenology of glutamine-repeat ag-
gregation—are described in detail, are thoroughly discussed,
and are appropriately referenced.
The widely diverse nature of the polyglutamine disease field
is apparent in this book. The work consists of 21 chapters writ-
ten by a variety of investigators who all study the molecular
basis of polyglutamine neurodegeneration (with the exception
of the final chapter, which is devoted to the tauopathies and
synucleinopathies, neurodegenerative disorders characterized by
proteinaceous inclusions, although not glutamine expansions in
these cases). After Peter Harper’s brief but excellent introductory
chapter that provides an overview of HD and its place within
the category of polyglutamine-repeat diseases, the remaining 20
chapters are divided into five sections. The first section consists
of four chapters discussing different mouse models of HD, as
well as their molecular implications. A fifth chapter describes
the first model of polyglutamine neurodegeneration in Dro-
sophila melanogaster. The two chapters devoted to the gener-
ation and characterization of the HD R6 mouse models provide
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a nice overview of this work and should serve as a useful in-
troduction for researchers who intend to launch studies using
the R6/1 or R6/2 transgenic mice developed by Gillian Bates’s
group. The next section consists of three chapters that provide
synopses of studies aimed at understanding polyglutamine dis-
ease pathology through the identification of interacting proteins,
examination of proteolytic cleavage, and analysis of protein ag-
gregation, all done for the most part in cell culture and in vitro
systems. The next four chapters comprise the third section and
are similar in subject matter and scope to the second section,
except that the contributors’ studies are focused upon the hun-
tingtin protein product. The fourth section attempts to address
the phenomenon of genetic instability, an interesting and im-
portant feature of all the trinucleotide-repeat diseases, including
disorders not caused by noncoding CAG repeats. The fifth and
final section of this book is a series of six chapters dealing with
a wide array of topics, ranging from the spinocerebellar ataxias
and their mouse models to Kennedy disease and dentatorubral-
pallidoluysian atrophy to the aforementioned tauopathy/synu-
cleinopathy chapter. The book is nicely illustrated and should
be accessible to non–molecular specialists and clinical geneticists.
When considering the various contributions that comprise
this volume, one does note substantial variability in terms of
the style and content of the successive chapters. I particularly
enjoyed the chapters that reviewed the generation and char-
acterization of the HD transgenic mice and the firstDrosophila
model, as it was nice to find all these data collated and sum-
marized in one place. Furthermore, these chapters struck a nice
balance between presenting experimental data and providing
a review/overview of the data. The cell culture and in vitro
studies presented in the following chapters shift from original
data publication–style papers to review-style papers, and this
unevenness underscores the fact that Glutamine Repeats and
Neurodegenerative Diseases: Molecular Aspects is the by-prod-
uct of a meeting, not a preconceived or deliberate construction.
The coverage given to CAG-repeat instability is rather scant
by comparison to the other topics, although these chapters
provide a meaningful introduction to a topic the understanding
of which lags far behind others in this field. The final series
of chapters make an especially nice finish to the work, even
though they comprise a veritable potpourri of topics and ex-
perimental approaches. Neurologists and medical geneticists
alike will find the chapter on the spinocerebellar ataxias from
Drs. Worth, Brice, and Wood informative and comprehensive.
In summary, one comes away from Glutamine Repeats and
Neurodegenerative Diseases: Molecular Aspects impressed that
the contributors have authoritatively summarized an enormous
wealth of data and stacks of important papers from the lit-
erature, much of which they themselves have generated. This
synthesis of the state of the field in early 1999 is bound to be
highly useful to graduate students, postdoctoral fellows, and
clinical trainees who are being introduced to the polyglutam-
ine-repeat diseases for the first time. As one might expect from
the relative importance of HD and the fact that it was the
second polyglutamine-expansion mutation to be uncovered,
the bulk of the emphasis of this book is placed on HD mo-
lecular research. The only problem with the work is that Glu-
tamine Repeats and Neurodegenerative Diseases: Molecular
Aspects provides us with a comprehensive overview of poly-
glutamine disease research as it was in mid-1999. In a field
that is moving as rapidly as this one, researchers of glutamine-
repeat diseases may find the work to be not quite up to date,
as recent developments in our understanding of polyglutamine
disease pathogenesis have yielded additional important para-
digms that require re-evaluation of previous studies. Such a
problem is not entirely unexpected, however, in the prepara-
tion of any book that deals with the pursuit of scientific knowl-
edge. Despite the 2-year information gap, it is worthwhile to
point out that certain key issues in the polyglutamine disease
field, namely the role of aggregates and the basis of genetic
instability, remain essentially unresolved. Importantly, the sem-
inal studies that divide researchers on how to interpret the
aggregation phenomenon are well laid out in many of the
chapters in this work and therefore retain their timeliness.
In the preface toGlutamine Repeats and Neurodegenerative
Diseases: Molecular Aspects,Drs. Harper and Perutz state that
their goals for this work are “to stimulate further the already
very active field, and to make it more accessible to clinicians
and workers in allied areas of neuroscience” (p. xi). By pre-
sentation of a wide-ranging overview of the polyglutamine
disease field, with chapters written concisely and authorita-
tively by leading workers in the field, I believe that these goals
have been achieved. As an introduction to polyglutamine dis-
ease research, this book does a wonderful job of offering cli-
nicians, medical geneticists, graduate students, and postdoc-
toral fellows a way to familiarize themselves with a rather
complicated and rapidly moving field. Indeed, I can think of
only one other volume—Wells and Warren’s Genetic Insta-
bilities and Hereditary Neurological Disease—whose subject
matter overlaps with the Harper and Perutz creation, and,
admittedly, that overlap is only partial. For these reasons,Glu-
tamine Repeats and Neurodegenerative Diseases: Molecular
Aspects is a welcome addition to my book collection.
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